Home / 2015 / August

Monthly Archives: August 2015

TGA Approves Hospira’s mAb Biosimilar

MELBOURNE, Australia, Aug. 19, 2015 /PRNewswire/ — Hospira today announced that InflectraTM (infliximab), the first monoclonal antibody (mAb) biosimilar therapy, has been registered in Australia.  This registration paves the way for the Federal Government to reduce the cost of some of the most expensive medicines on the Pharmaceutical Benefits Scheme (PBS). …

Read More »

Novartis to Buy GSK’s Investigational Multiple Sclerosis Drug for up to $1 Billion

Basel, August 21, 2015 – Novartis announced today that it has entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (GSK). Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for relapsing remitting multiple sclerosis (RRMS) and other autoimmune indications. Novartis previously …

Read More »

Raptor Acquires Cystic Fibrosis Drug in $418 Million Deal

NOVATO, Calif., Aug. 20, 2015 (GLOBE NEWSWIRE) — Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it has signed a definitive agreement with Tripex Pharmaceuticals to acquire Quinsair, the first inhaled fluoroquinolone approved for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adults with cystic fibrosis, expanding its …

Read More »

Study Finds Costs Associated with HCV Management More than Specialty Drug Spending

PHOENIX–(BUSINESS WIRE)–Primrose Healthcare has just released a compelling new study entitled “The burden of hepatitis C virus (HCV) disease in commercial and managed Medicaid populations.” This analysis explores a wide variety of factors that impact both the cost and outcomes attributed to HCV patients. The study, authored by renowned global …

Read More »